Sébastien Mas – CEO, Skyepharma
Skyepharma stands at a defining moment. With new shareholders, expanding high-potency and bioproduction capabilities and a sharpened focus on complex oral forms, the French CDMO is positioning itself for a…
Medpace is a global full-service CRO providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, regenerative medicine, gastrointestinal diseases, pediatrics, and orphan disease.
Established in 1992 in Cincinnati, Ohio, Medpace is historically a US based company. Since its inception, it has remained a physician led, therapeutically focused, CRO. Over the course of 20 years Europe has become an increasingly important market region. A full-time office in Lyon opened in 2012, while Medpace has been conducting business operations in France since 2005. Currently they have thirteen offices in Europe and have established themselves as an international CRO with a strong European presence.
Contact
Medpace France
235 cours Lafayette
69006 Lyon
France
Tel: +33 4 37 53 09 91
Skyepharma stands at a defining moment. With new shareholders, expanding high-potency and bioproduction capabilities and a sharpened focus on complex oral forms, the French CDMO is positioning itself for a…
ANSM’s Director General Catherine Paugam-Burtz offers a clear view of how France’s medicines agency is adapting to a fast-shifting landscape. She discusses ANSM’s role within the European regulatory system, the…
Pascaline Gervoson, CEO of PiLeJe, a family-owned French nutraceutical company, represents the second generation of leadership following her father’s founding vision in 1992. With 27 years within the organisation and…
ISISPHARMA’s story unfolds through the Dewavrin group’s evolution from textile manufacturing into a science driven portfolio spanning dermocosmetics and micronutrition. Grégoire Dewavrin explains how the brand has grown through a…
At a time when France’s healthcare landscape is being reshaped by regulatory change, market pressure, and shifting patient expectations, Fabrice Ruggeri, Country Manager of Organon France, is steering the affiliate…
Under the leadership of Nicolas Bardonnet, Promega France has expanded its role from a broad portfolio provider to a more collaborative partner supporting key human health applications. Bardonnet has integrated…
Benta Lyon is reshaping its industrial footprint with unusual speed, combining a fast-growing CDMO platform, an expanding French made generics portfolio and new sterile capabilities that will anchor its next…
argenx has moved from an antibody engineering start-up to one of Europe’s most closely-watched biotechs, advancing a pipeline that spans multiple autoimmune diseases. In this interview, François Rauch reflects on…
With over 25 years of experience at the crossroads of science and business, Pascal Villemagne, CEO of SEQENS, shares his vision for steering the French CDMO into a new era…
France’s territorial landscape is undergoing a profound shift, and departments are emerging as decisive actors in the response to medical deserts, demographic ageing and the widening gaps in prevention and…
Jerome Estampes, CFO and interim CEO of Guerbet France, discusses his journey from joining the company in 2019 through to his current dual role, navigating the challenges of generic competition,…
Alexion France is entering a pivotal phase as the rare-disease landscape becomes more competitive, more data driven and increasingly shaped by early access and clinical-trial performance. In this interview, Celine…
See our Cookie Privacy Policy Here
